RecruitingDrug trialIntrathecal Gene Therapy For SLC13A5 Citrate Transporter DisorderPhase 1/2, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of TSHA-105 in individuals with SLC13A5 Citrate Transporter Disorder